Robust assay performance is crucial when faced with the diagnosis of Acute or Acute Heart Failure MISPA 160 - THE COST TRANSPARENT AND FLEXIBLE SOLUTION TO MANAGE YOUR CARDIAC TEST REQUEST WORKFLOW With the continued development and enhancements in sensitivity of cardiac troponin assays, the future use of both CK-MB and Myoglobin in the area of AMI diagnosis is in question and is expected to decline over the coming years. However, these assays may still have a clinical utility but in lower volumes. The unique single test cartridge is perfect for both high and lower throughput assays and where the number of requests maybe unpredictable. Reagent wastage is eliminated as a result of the “one test, one cartridge” concept. IMPORTANCE OF MEASURING CK-MB As troponin remains elevated for around 5-7 days, the measurement of CK-MB can be used to detect reinfarction. CK-MB has been used to measure infarct size such that interventions can be done earlier in order to minimise the extent of myocardial damage. Fully Automated Immunoassay Analyzer Assay sensitivity, low levels of imprecision and a wide dynamic range are all critical factors to ensure you get the right result when time can be against you. The Mispa i60 cardiac panel of assays provides all of these key performance characteristics, together with robust instrumentation that offers reliability. Cardiac troponins are being considered as the preferred biomarker for diagnosis of acute myocardial infarction (AMI). The current European Society of Cardiology Acute Coronary Syndrome Guidelines recommend algorithms incorporating high sensitivity assays for: • Quicker acute myocardial infarction rule in/rule out. • The high negative predictive values allow for rapid exclusion of AMI and potential rapid movement of patients through the emergency department1. Assays defined as high sensitivity have to fulfill the following two criteria: • A coefficient of variation less than or equal to 10% at the 99th percentile value of the healthy reference population. • Concentrations above the assay’s limit of detection (LoD) are measurable in greater than 50% of healthy individuals1. The diagnostic utility of Troponin T remains challenging in patients with chronic kidney disease (CKD) as decreased renal clearance may affect circulating levels of this biomarker2. Patients with a wide spectrum of neuromuscular diseases can have elevated Troponin T levels in the absence of both clinical and Troponin I evidence of myocardial injury3 4. ASSAY CHARACTERISTICS - MISPA i60 HS TROPONIN I